Axsome Therapeutics (NASDAQ: AXSM) reported Q3 EPS of ($1.32), $0.13 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $57.79 million versus the consensus estimate of $55.48 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.